logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

XIAOMI-W (01810) spent approximately HKD 49.9574 million to repurchase 1.868 million shares on August 11.

date
19:26 11/08/2026
avatar
GMT Eight
Xiaomi Group-W (01810) announced that on August 11, 2026, it spent approximately HKD 49.9574 million to repurchase 1.868 million shares.
XIAOMI-W (01810) announced that it will spend approximately HKD 49.9574 million to repurchase 1.868 million shares on August 11, 2026.
Related Articles
HK Stock
In the first seven months, CHINA JINMAO (00817) accumulated a signed sales amount of 66.702 billion yuan, an increase of 7.92% year-on-year.
HK Stock
CNE TECH CORP (00611) issued a profit warning, expecting a mid-term net profit of no less than 30 million yuan, a decrease of no more than 65% compared to the same period last year.
HK Stock
CSPC PHARMA (01093): The Phase I clinical trial of SYS 6063 for the treatment of refractory relapse systemic lupus erythematosus has officially launched at the first center in China.
In the first seven months, CHINA JINMAO (00817) accumulated a signed sales amount of 66.702 billion yuan, an increase of 7.92% year-on-year.
HK Stock
CNE TECH CORP (00611) issued a profit warning, expecting a mid-term net profit of no less than 30 million yuan, a decrease of no more than 65% compared to the same period last year.
HK Stock
CSPC PHARMA (01093): The Phase I clinical trial of SYS 6063 for the treatment of refractory relapse systemic lupus erythematosus has officially launched at the first center in China.
HK Stock
RECOMMEND
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
icon
10/06/2026
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
icon
10/06/2026
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
icon
10/06/2026
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.